Initial Experience With Nalmefene in Alcohol‐Related Liver Disease: A Real‐World Retrospective Study
Nalmefene appears to be a safe and effective pharmacological option for reducing alcohol intake and improving liver function in patients with ALD. These findings support its use as part of a harm reduction approach for those unable to achieve complete abstinence.
Authors
- Junichi Hanatani (ORCID: https://orcid.org/0009-0001-9174-2477)
- Hiroyuki Masuda (ORCID: https://orcid.org/0000-0003-3288-0236)
- Hitoshi Yoshiji (ORCID: https://orcid.org/0000-0002-5243-8544)
- Akira Mitoro
- Takashi Inoue (ORCID: https://orcid.org/0000-0002-9672-2117)
- Koh Kitagawa (ORCID: https://orcid.org/0000-0001-5794-1512)
- Tadashi Namisaki (ORCID: https://orcid.org/0000-0002-3158-5318)
- Hiroaki Takaya (ORCID: https://orcid.org/0000-0002-4990-7573)
- Satoshi Iwai (ORCID: https://orcid.org/0000-0003-3575-5609)
- Akihiko Shibamoto
- Masayoshi Takami
- Norihisa Nishimura (ORCID: https://orcid.org/0000-0002-6295-3283)
- Kosuke Kaji (ORCID: https://orcid.org/0000-0002-1822-6759)
- Yukihisa Fujinaga (ORCID: https://orcid.org/0000-0003-2402-574X)
- Yuki Tsuji
- Shinya Sato
- Kiyoshi Asada
Institutions
- Nara Medical University (JP)
Publication Details
- Journal
- Hepatology Research
- Published
- 2025-08-16
- DOI
- https://doi.org/10.1111/hepr.70019
- Primary Topic
- Alcohol Consumption and Health Effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00